NOACs in the real world

Join Dr Torben Larsen for a discussion of his comprehensive paper: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Earn CME credits

In order to claim CME credits for watching the ‘Exploring re-circuit module’ and receive a certificate, please register on our eLearning platform. Following a brief pre-assessment, you will be able to view the module and can subsequently take the post-assessment. Your certificate of accreditation will become available following this.

Access CME Module

Highlights report

You can recap the learnings of this journal club by reading the short, comprehensive highlights report which details the key findings of the discussion.

Access highlights report


Dr Dr Torben Larsen

Aalborg University Hospital

Aalborg, Denmark


Despite the wealth of evidence demonstrating their ability to save lives, oral anticoagulants – including both warfarin and NOACs – are often avoided by clinicians, owing to the fear of iatrogenic internal bleeding. However, does this actually happen? This study of patient outcomes in a real-world setting demonstrates that not only do NOACs reduce the risk of stroke, some also feature significantly lower risks of death and major bleeding compared to warfarin.

View abstract Access full paper

  • Target audience

    This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.

  • Learning objectives

    After participating in this educational activity, participants will be able to:

    • Describe real-world safety and efficacy data for oral anticoagulants in patients with atrial fibrillation
  • Disclosures

    Prof John Camm:

    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

    Prof Torben Larsen:

    • On speakers Bureau for: Bayer, BMS-Pfizer, Roche Diagnostics, Boehringer Ingelheim, MSD, AstraZeneca, Takeda Pharma
    • Dr Larsen’s institution has received honoraria from: Janssen Scientific Affairs, LLC, Boehringer Ingelheim

    Staff and reviewer disclosures

    ACHL staff, PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Accreditation

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and PCM Scientific. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

    Credit designation

    The Academy for Continued Healthcare Learning designated this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Funding

    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.

    The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.